![](/img/cover-not-exists.png)
Phase II California Cancer Consortium trial of gemcitabine–eribulin combination (GE) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): tolerability and toxicity report (NCI-9653; 1UM1CA186717-01, NO1-CM-2011-00038)
Sadeghi, S., Groshen, S., Parikh, R., Mortazavi, A., Dorff, T., Hoimes, C., Pal, S., Levine, E., Doyle, L., Quinn, D., Newman, E., Lara, P.Volume:
72
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(17)30706-2
Date:
February, 2017
File:
PDF, 52 KB
english, 2017